In8Bio INAB
NASDAQ INAB
$1.05 +0.06 (+6.06%)
At close: Oct 23, 2026 · 4:00 PM EDT

In8Bio (INAB) Construction in Progress (2021 - 2022)

Updated

In8Bio (INAB) recorded Construction in Progress of $497,000 in Q1 2022, up 23.3% from the prior quarter.

Analysis

In8Bio (INAB) Construction in Progress (2021 - 2022) Analysis & Trends

At the end of FY2021, In8Bio reported Construction in Progress of $403,000.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Construction in Progress (Qtr)
1 Eli Lilly 1,199.50 Bn 1,168.08 Bn 19.71 Bn -
2 Johnson & Johnson 635.17 Bn 555.03 Bn 17.30 Bn -
3 AbbVie 504.69 Bn 477.85 Bn 12.70 Bn -
4 Merck 358.43 Bn 312.86 Bn 12.21 Bn -
5 Novartis Ag 288.36 Bn 252.75 Bn 11.24 Bn -
6 Astrazeneca 265.78 Bn 239.54 Bn 12.86 Bn -
7 Amgen 237.46 Bn 192.86 Bn 7.24 Bn -
8 Gilead Sciences 193.65 Bn 167.76 Bn 6.22 Bn -
9 Pfizer 171.05 Bn 118.00 Bn 10.94 Bn -
10 In8Bio 20.44 Mn -57.91 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2022 497,000.00
Dec 31, 2021 403,000.00
Sep 30, 2021 183,000.00
API Access

In8Bio Construction in Progress API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=construction-in-progress&ticker=INAB&period=max&api_key=YOUR_API_KEY